|1.||Gridelli, Cesare: 3 articles (03/2003 - 11/2002)|
|2.||Gridelli, C: 2 articles (01/2001 - 09/2000)|
|3.||Yu, Yinyi: 1 article (01/2015)|
|4.||Korom, Maria: 1 article (01/2015)|
|5.||Blevins, Tamara P: 1 article (01/2015)|
|6.||Morrison, Lynda A: 1 article (01/2015)|
|7.||Wang, Hong: 1 article (01/2015)|
|8.||Belshe, Robert B: 1 article (01/2015)|
|9.||Mitchell, Michelle C: 1 article (01/2015)|
|10.||Mittal, Manoj: 1 article (08/2010)|
|1.||Lung Neoplasms (Lung Cancer)
02/01/2006 - "NSCLC research still has relatively little material dedicated exclusively to the elderly, but recently interest has been growing, possibly due to the positive results of the most recent trials (Elderly Lung Cancer Vinorelbine Study Group (ELVIS), Southern Italy Cooperative Oncology Group (SICOG), Multicenter Italian Lung Cancer in the Elderly Study (MILES)). "
12/01/2002 - "First, the randomized Elderly Lung Cancer Vinorelbine Study Group (ELVIS) trial makes clear that elderly patients treated with vinorelbine plus best supportive care (BSC) have significantly improved survival and quality of life when compared with patients treated with BSC alone. "
11/01/2002 - "A phase III randomized trial (ELVIS [Elderly Lung Cancer Vinorelbine Italian Study]) demonstrated survival and quality-of-life benefits with single-agent vinorelbine versus best supportive care. "
01/01/2002 - "In the large comparative Elderly Lung Cancer Vinorelbine Italian Study (ELVIS), patients receiving vinorelbine monotherapy achieved an objective response rate of 19.7%. "
09/01/2000 - "A phase III randomized trial, named ELVIS (Elderly Lung Cancer Vinorelbine Italian Study), showed a survival and quality of life benefit of vinorelbine versus supportive care. "
|2.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/01/2001 - "The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. "
03/01/2003 - "The ELVIS (Elderly Lung cancer Vinorelbine Italian Study) trial demonstrated the tolerability and efficacy of VNR in elderly pts with advanced non-small cell lung cancer (JNCI 91: 66-72, 1999). "
08/01/1995 - "Paclitaxel plus carboplatin: an effective combination chemotherapy for advanced non-small-cell lung cancer or just another Elvis sighting?"
01/01/2001 - "This randomized, crossover, multiperiod trial involved 16 physicians who each reviewed two ELVIS and two control (text) cancer patient cases (total 32 ELVIS and 32 text cases). "
01/01/2001 - "The Edmonton Labeled Visual Information System (ELVIS) is a novel method of documenting clinical information because it is a pictorial method of representing cancer burden and treatment. "
04/01/2001 - "Our preclinical data indicate that therapeutic vaccination of patients with ELVIS-neu may reduce metastasis from HER2/neu-expressing breast and ovarian tumors."
01/01/2001 - "The data indicate that ELVIS aids the process of learning complex cancer patient histories."
01/01/2015 - "Clinical isolates and sera from the Herpevac Trial for Women were used in a colorimetric assay in which infection of tissue culture (lack of neutralization) was indicated by substrate metabolism by beta-galactosidase induced in the ELVIS cell line. "
12/01/1999 - "The ELVIS HSV Id test kit (an enzyme-linked virus-inducible system) (Diagnostic Hybrids, Inc.) uses genetically engineered BHK cells to produce a detectable enzyme, beta-galactosidase, upon infection with either herpes simplex virus (HSV) type 1 (HSV-1) or HSV-2. "
|5.||Wounds and Injuries (Trauma)
11/01/2007 - "Adrenal trauma: Elvis Presley Memorial Trauma Center experience."
01/01/2003 - "Data describing medically treated sport and active recreation injuries to Latrobe Valley residents aged over 4 years (about 70,000) were selected by postcode from three sources: the Victorian Admitted Episodes Dataset (hospital admissions), the Victorian Injury Surveillance System (presentations to hospital emergency departments), and the Extended Latrobe Valley Injury Surveillance (ELVIS) project (presentations to general practitioners). "
|1.||Combination Drug Therapy (Combination Chemotherapy)